Evaluation of bone mineral density in children receiving carbamazepine or valproate monotherapy

Acta Paediatrica Taiwanica

Volumn 48, Issue 6, 2007, Pages

  Chou, I Jun ^a   Lin, Kuang Lin ^a,b   Wang, Huei Shyong ^a   Wang, Chao Jan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

Author keywords

Bone mineral density; Carbamazepine; Valproate

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CARBAMAZEPINE; PHOSPHATE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMALE; FRACTURE; HUMAN; MALE; MONOTHERAPY; TREATMENT DURATION;

ADOLESCENT; ANTICONVULSANTS; BONE DENSITY; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 42149174266     PISSN: 16088115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986; 314:1676-86.
2. Crosley CJ, Chee C, Berman PH. Rickets associated with long-term anticonvulsant therapy in a pediatric outpatient population. Pediatrics 1975; 56:52-7.
3. Pavlakis SG, Chusid RL, Roye DP, Nordli DR. Valproate therapy: Predisposition to bone fracture? Pediatr Neurol 1998; 19:143-4.
4. Ecevit C, Aydogan A, Kavakli T, Altinoz S. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 2004; 31:279-82.
5. Voudris K, Moustaki M, Zeis PM, et al. Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy. Seizure 2002; 11:377-80.
6. Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002; 43:1488-92.
7. Rieger-Wettengl G, Tutlewski B, Stabrey A, et al. Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics 2001; 108:E107.
8. Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001; 42:1141-7.
9. Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000; 47:385-8.
10. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999; 38:93-8.
11. Akin R, Okutan V, Sarici U, Altunbas A, Gokcay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998; 19:129-31.
12. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995; 127:256-62.
13. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7:1-6.
14. Ellis KJ, Shypailo RJ, Hardin DS, et al. Z-score model for assessment of bone mineral content in pediatric diseases. J Bone Miner Res. 2001; 16:1658-64.
15. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004; 5:S24-9.
16. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57:445-9.
17. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58:1348-53.